

S/N 09/703,350

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MEHRABAN ET AL. Examiner: G. NICKOL
Serial No.: 09/703,350 Group Art Unit: 1642
Filed: OCTOBER 31, 2000 Docket No.: 11669.213USU1
Confirmation No.: 3065 Customer No.: 23552
Title: DIFFERENTIALLY EXPRESSED GENES INVOLVED IN
ANGIOGENESIS, THE POLYPEPTIDES ENCODED THEREBY,
AND METHODS OF USING THE SAME

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV 408488347 US
Date of Deposit: September 2, 2004

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, Mail Stop RCE, P.O. Box 1450, Alexandria, VA 22313-1450.

By:

Sheryl A. Boerboom
Name: Sheryl A. Boerboom

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Mail Stop RCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a

reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.


Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.



Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: September 2, 2004


Katherine M. Kowalchyk
Reg. No. 36,848

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

11669.213USU1

Application Number:

09/703,350

Applicant: MEHRABAN ET AL.

Filing Date: 10/31/00

Group Art Unit: 1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Davis, G. et al., "An $\alpha 2 \beta 1$ Integrin-Dependent Pinocytic Mechanism Involving Intracellular Vacuole Formation and Coalescence Regulates Capillary Lumen and Tube Formation in Three-Dimensional Collagen Matrix", <u>Experimental Cell Research</u> , 224:39-51 (1996)
		Filvaroff, E. et al., "Stanniocalcin 1 Alters Muscle and Bone Structure and Function in Transgenic Mice", <u>Endocrinology</u> , 143(9):3681-3690 (2002)
		Kahn, J. et al., "Gene Expression Profiling in an <i>in Vitro</i> Model of Angiogenesis", <u>American Journal of Pathology</u> , 156(6):1887-1900 (June 2000)
		Presta, L. et al., "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders", <u>Cancer Research</u> , 57:4593-4599 (Oct. 15, 1997)
		Wary, K. et al., "Analysis of VEGF-responsive Genes involved in the activation of endothelial cells", <u>Molecular Cancer</u> , 2:25 (July 9, 2003)
		Zlot, C. et al., "Stanniocalcin 1 is an Autocrine Modulator of Endothelial Angiogenic Responses to Hepatocyte Growth Factor", <u>The Journal of Biological Chemistry</u> , 278(48):47654-47659 (Nov. 28, 2003)

23552

PATENT TRADEMARK OFFICE

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.